argenx SE Overview
Pro stress-test →Argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. The company reported 2025 sales of $4.15B with a 90% increase and is treating approximately 19,000 patients globally. The company is led by a world-class FcRn antibody platform anchored by its flagship drug VYVGART.
Strategic Profile
Pro stress-test →VYVGART is leading the growth of all biologics in myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP), proving the power of argenx's approach to redefine treatment paradigms through evidence generation and more effective, convenient medicines. By the end of 2026, the pipeline will include four Phase 3 molecules and a total of 10 molecules in clinical development.
Competitive Landscape
Pro stress-test →Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases, with its lead product VYVGART (efgartigimod) approved by FDA in December 2021 for generalized myasthenia gravis and approved in 2024 for chronic inflammatory demyelinating polyneuropathy. Main competitors include other immunology and rare disease companies developing complementary modalities and therapies.
Industry Context
argenx SE operates in Biopharmaceutical / Immunology.
Key facts
Founded: 2008 · Headquarters: Amsterdam, Netherlands · Revenue: $4.15B · Market cap: $52.36B